Overview

  • Product name
    Anti-GFAP antibody [G-A-5] (Cy3 ®)
    See all GFAP primary antibodies
  • Description
    Mouse monoclonal [G-A-5] to GFAP (Cy3 ®)
  • Conjugation
    Cy3 ®. Ex: 552nm, Em: 565nm
  • Specificity
    Recognizes an epitope localized on the carboxy terminal Cys II fragment of GFAP and the N-terminal part of the tail sequence of the molecule.
  • Tested applications
    Suitable for: IHC-Fr, IHC-P, ICC/IFmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Chicken, Cat, Human, Pig, Goldfish
  • Immunogen

    Purified GFAP from pig spinal cord

  • Positive control
    • Rat cerebellum.
  • General notes

    This product or portions thereof is manufactured under license from Carnegie Mellon University under U.S. Patent Number 5,268,486 and related patents. Cy and CyDye are trademarks of GE Healthcare Limited.

    Monoclonal Anti-Glial Fibrillary Acidic Protein (GFAP) conjugated to Cy3®. The Cy3®-antibody conjugate is extensively dialyzed to remove unbound Cy3®.

Properties

Applications

Our Abpromise guarantee covers the use of ab49874 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-Fr 1/400.
IHC-P 1/400. The epitope recognized by the antibody is partially sensitive to prolonged formalin fixation, but is resistant to alcohol-fixation followed by paraffin-embedding and to acetone-fixation of frozen sections.
ICC/IF Use at an assay dependent dilution. PubMed: 20211723

Target

  • Function
    GFAP, a class-III intermediate filament, is a cell-specific marker that, during the development of the central nervous system, distinguishes astrocytes from other glial cells.
  • Tissue specificity
    Expressed in cells lacking fibronectin.
  • Involvement in disease
    Defects in GFAP are a cause of Alexander disease (ALEXD) [MIM:203450]. Alexander disease is a rare disorder of the central nervous system. It is a progressive leukoencephalopathy whose hallmark is the widespread accumulation of Rosenthal fibers which are cytoplasmic inclusions in astrocytes. The most common form affects infants and young children, and is characterized by progressive failure of central myelination, usually leading to death usually within the first decade. Infants with Alexander disease develop a leukoencephalopathy with macrocephaly, seizures, and psychomotor retardation. Patients with juvenile or adult forms typically experience ataxia, bulbar signs and spasticity, and a more slowly progressive course.
  • Sequence similarities
    Belongs to the intermediate filament family.
  • Post-translational
    modifications
    Phosphorylated by PKN1.
  • Cellular localization
    Cytoplasm. Associated with intermediate filaments.
  • Information by UniProt
  • Database links
  • Alternative names
    • wu:fb34h11 antibody
    • ALXDRD antibody
    • cb345 antibody
    • etID36982.3 antibody
    • FLJ42474 antibody
    • FLJ45472 antibody
    • GFAP antibody
    • GFAP_HUMAN antibody
    • gfapl antibody
    • Glial fibrillary acidic protein antibody
    • Intermediate filament protein antibody
    • wu:fk42c12 antibody
    • xx:af506734 antibody
    • zgc:110485 antibody
    see all

Anti-GFAP antibody [G-A-5] (Cy3 ®) images

  • Immunocytochemistry/Immunofluorescence analysis of chicken astrocytes labelling GFAP (red) with ab49874. Nuclei stained using DAPI (blue). Cells were fixed with methanol for 15 minutes, washed in PBS and permeabilized with PBST for 10 minutes. Cells were then washed and blocked using 1% BSA in PBST for 30 minutes. Cells were incubated with the primary antibody (1:400 in blocking solution) for 1 hour at room temperature or overnight in a humid chamber in 4°C. 

References for Anti-GFAP antibody [G-A-5] (Cy3 ®) (ab49874)

This product has been referenced in:
  • Liu Y  et al. PD-L1 expression by neurons nearby tumors indicates better prognosis in glioblastoma patients. J Neurosci 33:14231-45 (2013). Read more (PubMed: 23986257) »
  • Dotan S  et al. An avian model for the reversal of neurobehavioral teratogenicity with neural stem cells. Neurotoxicol Teratol 32:481-8 (2010). ICC/IF ; Chicken . Read more (PubMed: 20211723) »

See all 2 Publications for this product

Product Wall

Abcam guarantees this product to work in the species/application used in this Abreview.
Application
Immunohistochemistry (Frozen sections)
Sample
Mouse Tissue sections (Brain)
Specification
Brain
Fixative
Acetone
Permeabilization
No
Blocking step
PBS +1% BSA +1% Ovalbumine +1% goat serum as blocking agent for 20 minute(s) · Concentration: 1% · Temperature: 22°C
Username

Abcam user community

Verified customer

Submitted Sep 25 2012

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up